Cefadroxil

Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries. Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. “We are very excited to share validation data of our MRD assay. SABCS gives us the opportunity to showcase our clinical expertise in the prevention and treatment of early and advanced breast cancer,” said George Daneker, MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. “Myriad is one of the only labs that can offer germline and tumor genomic testing, combined with customizable workflow solutions and point-of-care patient education sessions. Our test results are supported by treatment-focused reporting, concordance checks between germline and tumor genomic results, and a summary sheet designed to help oncologists and breast surgeons interpret actionable insights more effectively.” Myriad Genetics Data Presentations Spotlight Presentation: Session 16, PS16-01: Polygenic Risk Date: Thursday, Dec. 12, 2024, 5:30-7:00 pm (CST), Hemisfair Ballroom 3 Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics The presentation will share longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors. Rapid-Fire Presentation: RF1-06 Date: Wednesday, Dec. 11, 2024, 12:00-12:50 pm (CST), Hall 1 Presenter: Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics Dr. Johansen Taber will share data detailing the association of polygenic-based breast cancer risk prediction with patient management. Poster Presentation: P2-04-23 Date: Wednesday, Dec. 11, 2024, 5:30-7:00 pm (CST), Halls 2-3 Presenter: Ashley Acevedo, PhD, Staff Computational Scientist, Myriad Genetics This poster shares the analytical validation of a high-definition tumor-informed Molecular Residual Disease (MRD) assay to demonstrate robust detection at low-tumor fractions, which are common in breast cancer. Poster Presentation: P3-02-10 Date: Thursday, Dec. 12, 2024, 12:30-2:00 pm (CST), Halls 2-3 Presenter: Holly Pederson, MD, Cleveland Clinic Dr. Pederson will share her evaluation of a polygenic risk score as a predictor of breast cancer, triple-negative breast cancer, and early-onset disease in Hispanic women. In addition to data presentations, Myriad will welcome attendees to its booth (#1327) during exhibition hours. Among the Myriad products highlighted in the company’s SABCS exhibit are: MyRisk® Hereditary Cancer Test evaluates 48 genes to help healthcare providers identify their patients’ risk of developing 11 different types of hereditary cancer. MyRisk’s clear, actionable results are the foundation for personalized care plans to help patients make confident, informed decisions about medical management. MyRisk with RiskScore® provides unaffected patients with a comprehensive, personalized assessment of the five-year risk and remaining lifetime risk of developing breast cancer.Precise Tumor® Molecular Profile Test is a pan-cancer solid tumor comprehensive genomic profiling test that helps clinicians with straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic result.MyChoice® CDx is one of the most comprehensive homologous recombination deficiency (HRD) tests available, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The MyChoice test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions).EndoPredict® Breast Cancer Prognostic Test is for patients with ER+, HER2-, node negative or node positive breast cancer. The test provides three individualized results used to help determine the most appropriate breast cancer treatment. About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com. Safe Harbor Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company will present new data at SABCS and that the company’s new data that will be shared at SABCS will show how the company’s second-generation tumor-informed MRD assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com Media Contact Glenn Farrell (385) 318-3718 PR@myriad.com

Advances in precision oncology have allowed patients to access innovative life-saving therapies when they previously had few, or no, other treatment options. But highly personalized medicine raises new challenges too, as developers must develop companion diagnostics (CDx) assays alongside novel therapeutics so clinicians can match patients with the most appropriate treatment.Unfortunately, developers often select an NGS solution for clinical trials without reflecting on how it may impact CDx development and commercialization later, says Jane Li, Senior Director, Global Companion Diagnostics at Thermo Fisher Scientific. This can be devastating for a program. If you run out of samples in the middle of CDx development, for example, you may have little or no opportunity to get back on track.Identifying challenges to CDx development and commercializationFirst and foremost, theres the issue of tissue loss. Clinical trial sites that send away patient tissues for testing or rely on NGS technologies that require more nucleic acid input typically dont get that sample back to use in CDx development, Li explains. As a result, developers may only have access to a limited bank of tissues with which to develop their assay.Theres also the challenge of consistency: Trial sites who create laboratory-developed tests (LDTs) may develop a range of testing protocols that increases the risk for variability across sites. Well often see different sites in different areas create their own LDT, but when you go to commercialize your therapy, you need to work with one CDx assay, explains Binh Nguyen, Vice President of Medical Science, Thermo Fisher Scientific. Theres always a risk that these LDTs wont be concordant, and youll need to account for that variability during the regulatory process.Finally, traditional NGS technologies that require more sample input negatively impact the stages of therapeutic development, including CDx and commercialization. Higher rates of tissue failure can impede enrollment at the start of a trial, limiting the number of samples available for CDx development. Less optimal methods also utilize more tissue, increasing the chance that CDx developers may use up entire samples without yielding usable results.An ideal NGS technology helps developers overcome key challengesAccess to the optimal technology allows developers to:Retain tissues on-site and prevent sample lossThe ideal NGS technology allows for decentralization:The option for smaller medical centers to screen patient samples on-site, rather than sending away biopsies at a major medical center, which can result in the loss of the sample. Using a decentralized testing model during clinical trials means developers are more likely to be able to access those same tissue banks for CDx development.Achieve consistency across sites to scale globallyThe ability to conduct sensitive testing in-house also means sites are less likely to rely on LDTs for site-specific CDx assays. As a result, developers have greater ability to use consistent protocols across each site, sidestepping the need to demonstrate concordance across multiple LDTs when submitting a CDx assay for approval.Achieving consistent processes across a decentralized network of sites is especially important for global scalability. If youre relying on a central lab in the U.S. for CDx a very common approach in the United States that might work domestically, but wont support your expansion to other countries says Li. Moving to a decentralized model, where you can distribute CDx tests to any hospital in any country, helps you expand therapy access globally. It means you can develop one CDx assay and it will work anywhereSetting your program up for success 1. Look ahead to CDx development and commercialization when selecting a solution for clinical trialsThe NGS technology you use during clinical trials has a direct impact on every step that occurs downstream, so its important to keep your long-term needs in mind from the start. Consider working with an end-to-end provider that will allow you to use the same technology throughout, suggests Nguyen.2. Seek out a partner with a proven track record of excellenceYoull glean additional benefits by selecting an end-to-end partner who can offer technical and regulatory support, too, advises Li.Getting a drug approved is no easy feat, and getting a CDx approved is no easy feat. Getting them both approved together is even harder, she says. Your CDx partner should have experience helping you navigate approvals with regulatory agencies in each of the global markets youre targetingConsider, too, how an NGS provider can support your project timelines and offer the support you need to keep the program on schedule. Any CDX development timeline is always important to the drug, but youll always run into a surprise or two that has the potential to cause delays, Li says. An ideal partner can help you anticipate and mitigate any challenges that might arise to deliver on time.In precision oncology, time is always of the essence, and the optimal NGS solution can help you hit your milestones during clinical trials, throughout CDx development and into global commercialization.Thermo Fisher Scientific leverages their global infrastructure and expertise to provide widely-used capabilities, from streamlining clinical research to accelerating targeted therapeutic and companion diagnostic development and global commercialization. To learn more,visit us online. '